Hot Products

Ginsenoside Rc
Catalog No: CFN99973

Ginsenoside Rc exhibits anti-diabetic, anti-adipogenic, anticancer and anti-inflammatory activities; it can attenuate inflammatory symptoms of gastritis, hepatitis and arthritis, and it can significantly enhance glucose uptake by inducing ROS generation, which leads to AMPK and p38 MAPK activation. Rc enhances GABA receptorA (GABAA)-mediated ion channel currents (IGABA), it also inhibits the expression of TNF-α and IL-1β.
Ginsenoside Rd
Catalog No: CFN99975

Ginsenoside Rd, a minor ginseng saponin, has several pharmacological activities such as immunosuppressive activity, anti-inflammatory activity, immunological adjuvant, anti-cancer activity and wound-healing activity. Rd inhibits TNFα-induced NF-κB transcriptional activity with an IC50 of 12.05±0.82 μM in HepG2 cells. Rd inhibits expression of COX-2 and iNOS mRNA. Rd also inhibits Ca2+ influx. Rd inhibits CYP2D6, CYP1A2, CYP3A4, and CYP2C9, with IC50s of 58.0±4.5 μM, 78.4±5.3 μM, 81.7±2.6 μM, and 85.1±9.1 μM, respectively.
Ginsenoside Rd2 (Quinquenoside L10)
Catalog No: CFN95231

Reference standards.
Ginsenoside Re
Catalog No: CFN99974

Ginsenoside Re is a major ginsenoside in ginseng and belongs to 20(S)-protopanaxatriol group. It has diverse in vitro and in vivo effects, including anti-diabetic, vasorelaxant, antihyperlipidemic, anti-ischemic, angiogenic, antioxidant, and anti-inflammation actions. It also exhibits potent neuroprotective effects against neuroinflammation in a murine model of ALS. Re increases HCAEC outward current via SKCa channel activation; it also increases the proliferation of CD4+ T cells with decreases cell death, and enhances viability of CD4+T cells through the regulation of IFN-γ-dependent autophagy activity.
Ginsenoside Rf
Catalog No: CFN99976

Ginsenoside Rf is a trace component of ginseng root, which has antinociception, analgesia, anti-inflammatory, and anti-cancer activities, it induces G2/Mphase cell cycle arrest and apoptosis in human osteosarcoma MG-63 cells through the mitochondrial pathway. Rf can act through a novel G protein-linked receptor in the nervous system by inhibiting N-type Ca2+ channel. Rf significantly reduces the production of IL-1β, IL-6, TNF-α, NO, and ROS, and suppresses TNF-α/LPS-induced NF-κB transcriptional activity.
Ginsenoside Rg1
Catalog No: CFN99967

Ginsenoside Rg1 has antiaging, anti-platelet activation, promotion of wound healing, and neuroprotective effects, it has protective effect against Aβ25-35-induced toxicity in PC12 cells,might be through the insulin-like growth factor-I receptor (IGF-IR) and estrogen receptor (ER)signaling pathways. Ginsenoside Rg1 is a desirable agent for enhancing CD4+ T-cell activity, as well as the correction of Th1-dominant pathological disorders, which by increasing Th2 specific cytokine secretion and by repressing Th1 specific cytokine production. It increased the expression of the vascular endothelial growth factor (VEGF) mRNA and reduced ERK pathway, expression of transforming growth factor beta (TGF-β) mRNA.
Ginsenoside Rg2
Catalog No: CFN99968

Ginsenoside Rg2 has therapeutic potential for type 2 diabetic patients, it also may represent a potential neurorestorative treatment strategy for vascular dementia or other ischemic insults, has protective effects against H2O2-induced injury and apoptosis in H9c2 cells. Ginsenoside Rg2 suppresses the hepatic glucose production via AMPK-induced phosphorylation of GSK3β and induction of SHP gene expression, regulates the 5-HT3A receptors that are expressed in Xenopus oocytes, inhibits nicotinic acetylcholine receptor-mediated Na+ influx and channel activity.
Ginsenoside Rg3
Catalog No: CFN99969

Ginsenoside Rg3 is the main component of Red ginseng, it inhibits Na+ and hKv1.4 channel with IC50s of 32.2±4.5 and 32.6±2.2 μM, respectively, it also inhibits Aβ levels, NF-κB activity, and COX-2 expression. Ginsenoside-Rg3 possesses an ability to inhibit the lung metastasis of tumor cells, and the mechanism of its antimetastatic effect is related to inhibition of the adhesion and invasion of tumor cells, and also to anti-angiogenesis activity. It is a novel drug, capable of inhibiting the early of scarring (HS) and later HS.
Ginsenoside Rg4
Catalog No: CFN90572

Reference standards.
Ginsenoside Rg5
Catalog No: CFN92643

Ginsenoside Rg5 plays a novel role as an IGF-1R agonist, promoting therapeutic angiogenesis and improving hypertension without adverse effects in the vasculature, it can ameliorate lung inflammation possibly by inhibiting the binding of LPS to toll-like receptor (TLR)-4 on macrophages. Ginsenoside Rg5 blocks cell cycle of SK-HEP-1 cells at the Gl/S transition phase by down-regulating cyclin E-dependent kinase activity and that the down-regulation of cyclin E-dependent kinase activity is caused mainly by induced CDK2 inhibitor, p21Cip/WAF1 and decreased levels of cyclin E.